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The articles in this Compendium present first findings from the baseline case-control study
of the OPPERA Program, a series of studies designed to identify risk factors for onset and
persistence of painful Temporomandibular Disorders (TMD). This first series of manuscripts
represents precursors to the ultimate goal of the OPPERA Program study, which is to build
and then test a multivariable model designed to identify causal determinants of new onset
TMD, as well as its chronicity. Embedded in OPPERA’s baseline phase was a case-control
study of chronic TMD, which collected extensive phenotypic and genotypic data from
individuals with examiner-classified TMD arthralgia, myalgia, or both (“TMD cases”) and
people who were found not to have TMD when examined (“controls”). The heuristic model
guiding the OPPERA study hypothesizes that development and clinical manifestation of
TMD is driven by two global intermediate phenotypes, psychological distress and pain
amplification, which in turn are influenced by both genetic factors and environmental
exposures.6 To address the model’s hypotheses, phenotypic data were collected across
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multiple domains, including socio-demographic, clinical, psychosocial, pain sensitivity, and
autonomic function. Genetic data were also obtained in order to identify potential biological
pathways underlying these intermediate phenotypes and thereby contributing causally to the
development of TMD. After an overview, which provides the background and conceptual
foundation for OPPERA, each of the subsequent articles reports associations between a
particular phenotypic domain and TMD while the final article presents genetic associations
with TMD. Rather than attempting a comprehensive analysis of this rich and complex
dataset, the purpose of this first series of publications is to present the OPPERA data
collection methods and to provide descriptive findings from this baseline phase. Future
manuscripts will directly address the primary and secondary hypotheses of the OPPERA
program.
Consistent with the epidemiological approach to case-control studies, this series of papers
reports odds ratios as measures of the degree of association between putative risk factors and
TMD.10 For the numerous risk factors measured as continuous variables, such as
psychological scales, standardized odds ratios were computed, representing the change in
odds of TMD associated with an increase of one standard deviation of the continuous
variable. The term “risk factor” is used broadly to represent variables (both etiologic events
and characteristics) present prior to onset of TMD as well as those that occur during or after
onset to exacerbate the symptoms of TMD. The variables of interest range from external
causes of tissue damage to psychological and physiological processes affecting pain
perception. Also included are commonly-occurring genetic variants that regulate biological
pathways influencing those processes. Thus, across all manuscripts, the term “risk factor”
conveys association and is not intended to imply causal influence or even temporal
sequence. Below, we briefly summarize and integrate the major findings from each article
and discuss future plans to elucidate factors underlying the development of TMD within the
OPPERA Program.
Maixner, et al: Overview of the OPPERA Study
The initial article provides a brief historical overview of research exploring the
epidemiology and risk factors for TMD, and discusses the development of the OPPERA
conceptual model, providing additional definition of important constructs.6 Based primarily
on cross-sectional designs, previous investigators had identified potential risk factors for
TMD, including: demographic (e.g. gender and age) and clinical (e.g. presence of other pain
conditions) factors; pain amplification in the form of enhanced responses to experimentally-
induced painful stimuli; and psychosocial factors, such as affective distress, somatic
awareness, and psychosocial stress. The more recently developed and burgeoning literature
regarding genetic influences on pain in general, and specifically on TMD, provides strong
support for a genetic contribution to development of TMD. The aims and structure of the
OPPERA Program are then presented. In addition to providing a useful conceptual
foundation for the OPPERA Program, this overview article informs readers of the
complexity of this project and acknowledges the invaluable support of both our Data
Coordinating Center (Battelle Memorial Institute) and the National Institute of Dental and
Craniofacial Research (NIDCR).
Slade, et al: OPPERA Methods, Recruitment, and Socio-demographic
Findings
Slade et al. 11 present a thorough description of study designs for the OPPERA prospective
cohort study, which is ongoing, and the baseline case-control study of 185 TMD cases and
1,633 controls, ages 18–44 years, which is the focus of this Compendium. Study
methodology is also provided in detail, including: recruitment methods, inclusion/exclusion
Fillingim et al. Page 2













and case-classification criteria, data collection procedures, training and calibration of
clinical examiners, and methods for longitudinal follow-up of participants. The assumptions
underlying sample size justification, the approach to data management and quality
assurance, and the data analytic methods employed across all phenotypic domains in the
baseline case-control study are also described.
One goal in selecting four study sites was to create demographic diversity in the cohort of
people recruited for the OPPERA project. Another goal of recruitment was to select a
community-based cohort of volunteers, both for cases and controls. The findings suggested
that both goals were achieved. There was marked socio-demographic diversity between sites
while within sites, the characteristics of OPPERA participants were generally comparable
with population Census data from counties including and surrounding the study site. More
than two thirds of TMD cases had first developed the condition at least three years prior to
enrollment, though one quarter had never sought health care for their pain, and only 38%
had received treatment for TMD from a health care professional within the preceding six
months. The latter finding illustrates that the group of TMD cases comprised both patients
receiving care and people with pain that was not currently managed with visits to a health
care professional.
Greater age, female gender, and white racial/ethnic group were all associated with increased
odds of TMD. Greater odds of TMD were modestly associated with higher educational
attainment, though not with other markers of socioeconomic status. The four-fold greater
odds of TMD in females relative to males and the pattern of age- and gender- associations
were strikingly similar to benchmark data from the US National Health Interview Survey.
Some of these findings confirm previous epidemiologic results, for example, gender
differences in TMD prevalence have been well-documented.5 However, limited and
conflicting evidence exists regarding the association of age, ethnic/racial group and
socioeconomic status with TMD. The higher frequency of TMD observed in non-Hispanic-
Whites than in other racial/ethnic groups and the lack of a socio-economic gradient is in
marked contrast to the pattern of disparities seen for most other health conditions 12.
Ohrbach, et al: OPPERA Clinical Findings and Pain Symptoms
The manuscript by Ohrbach et al8 presents clinical findings from the OPPERA case-control
study, and describes methods for collecting phenotypic variables across multiple clinical
domains, including: history of trauma, parafunctional behaviors, other pain or functional
disorders, clinical signs and symptoms, anthropometric measures, and medical history.
Several of these measures fall within the “environmental contribution” depicted in the
OPPERA heuristic model, while some others represent sub-clinical signs and symptoms of
TMD, or represent comorbid pain conditions that can occur with TMD. The findings verify,
as expected, that cases not only reported greater facial pain severity and pain-related
interference than controls, but also greater limitations in jaw function, more frequent joint
noises (clicking, crepitus), increased pain with function, and enhanced palpation sensitivity
compared to controls. Numerous case-control differences were also observed in putative risk
factors, with cases reporting greater occurrence of jaw injury, increased numbers of
parafunctional behaviors, and higher frequency of other pain conditions, including headache,
back pain, and irritable bowel syndrome. For several of those putative risk factors, odds
ratios of five or more were observed, signifying strong associations with TMD. An
important consideration noted by Ohrbach and colleagues 8 relates to the lack of information
regarding temporal sequencing of many potential risk factors and TMD onset, such that
causal relationships between experience of potential “risk factors” and the development of
TMD cannot be inferred. Indeed, a given variable, such as parafunctional behaviors, could
represent an antecedent causal contributor, an exacerbating factor in patients with existing
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TMD, or simply a consequence of experiencing TMD-related pain. OPPERA’s prospective
cohort study will be able to address these issues, because it will establish whether or not
potential risk factors are present prior to onset of TMD. However, the current case-control
study cannot address the question for the many potential risk factors that might vary
throughout a person’s lifetime. Given that many of the clinical variables are directly related
to the signs or symptoms used to classify TMD, these issues related to causal inferences are
particularly salient in this manuscript; however, this issue applies across all phenotypic
domains and will be further discussed below.
Fillingim, et al: Psychosocial Findings from the OPPERA Study
Fillingim et al3 present associations between TMD and psychosocial measures representing
the intermediate phenotype of “psychological distress” as specified in the OPPERA heuristic
model. Based on published literature, self-report instruments were administered assessing
psychosocial phenotypes across several conceptual domains, including: personality/global
psychological adjustment, mood/affect, psychosocial stress, somatic awareness, and pain
coping and catastrophizing. Findings indicated case-control differences across all domains,
with the strongest associations observed for somatic awareness, where standardized odds
ratios exceeded 2.0. Moderately strong associations were observed for measures of affective
distress and catastrophizing. Principal component analysis (PCA) was performed in the
control sample to identify latent constructs across the multiple psychological measures,
which yielded a model with the following four components: 1) Stress and Negative
Affectivity, 2) Global Psychological Symptoms, 3) Passive Pain Coping (including
catastrophizing), and 4) Active Pain Coping. These PCA findings indicate that multiple
underlying psychological constructs are present and are important to consider as potential
risk factors for TMD. While previous studies have examined psychological function in
patients with TMD 1,2,9, the OPPERA assessment battery represents perhaps the most
comprehensive evaluation to date of psychological phenotypes in people with TMD. Of
particular note is the finding that somatic awareness showed the strongest association with
TMD case status, rather than more traditional psychological risk factors such as mood or
perceived stress. As noted for the clinical data, psychosocial phenotypes such as increased
psychological distress, somatic awareness, and maladaptive pain coping, may represent
consequences and/or exacerbating factors rather than etiologic factors contributing to onset
of TMD, a possibility to be directly evaluated in the prospective study.
Greenspan, et al: Quantitative Sensory Testing Findings from the OPPERA
Study
Greenspan et al.4 present the findings regarding experimental pain sensitivity, which aims to
operationalize the intermediate phenotype of “pain amplification” as specified in the
OPPERA heuristic model and further defined in the Overview paper.6 The manuscript
describes in detail the OPPERA quantitative sensory testing (QST) procedures, which were
used to characterize multiple aspects of experimental pain sensitivity, including: sensitivity
to pressure, mechanical cutaneous, and heat pain stimuli, as well as more dynamic measures
of temporal summation of heat and mechanical pain. Statistically significant case-control
differences emerged for most measures of pain sensitivity, with the largest differences
observed for pressure pain thresholds and cutaneous mechanical pain threshold.
Standardized odds ratios of 2.0 or more, reflecting strong associations, were observed even
when the measurements were made on the shoulders, arm and hand, well away from the
temporomandibular joints, muscles and related tissues. Using data from the controls, PCA
identified five latent constructs in the QST data: (1) heat pain ratings, (2) heat pain
aftersensations and tolerance, (3) mechanical cutaneous pain sensitivity, (4) pressure pain
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thresholds, and (5) heat pain temporal summation. Overall, these findings indicate that TMD
cases show statistically significantly greater extracranial pain sensitivity across multiple
QST domains, and that measures of pressure pain sensitivity are particularly strongly
associated with odds of TMD. The prospective study will allow determination of whether
this state of pain amplification represents a premorbid risk factor for development of new
onset TMD.
Maixner, et al: Autonomic Findings from the OPPERA Study
In the next article in the series, Maixner and colleagues 7 present novel findings regarding
autonomic function in TMD cases and controls. In the OPPERA heuristic model, autonomic
function is characterized as a putative mechanism contributing to pain amplification. As
Maixner and colleagues note, several lines of evidence implicate disruptions of
autonomically-mediated pain inhibitory pathways in chronic pain conditions. Given its
comprehensive autonomic phenotyping, the OPPERA Program has the opportunity to
determine for the first time whether autonomic dysregulation represents a potentially causal
risk indicator for TMD.
The OPPERA Program performed extensive autonomic phenotyping, including the
following measures: blood pressure, heart rate, heart rate variability (HRV), and indirect
measures of baroreflex sensitivity, all of which were assessed at rest and in response to a
physical and a psychological stressor. Several autonomic measures differed between cases
and controls, such that greater odds of TMD was associated with increased heart rate,
reduced heart rate variability, and possibly reduced baroreflex sensitivity across all
experimental procedures. Odds ratios of 1.2 – 1.4 were found for the statistically significant
associations, indicating generally modest effects of greater heart rate and lower
parasympathetic tone on odds of TMD. PCA of the autonomic measures from the control
sample identified five components: 1) blood pressure (across all experimental tasks), 2)
HRV during psychological stress (i.e. the Stroop test), 3) heart rate (across all experimental
tasks), 4) resting HRV, and 5) HRV during physical stress (i.e. orthostatic challenge). Taken
together, the findings suggest a pattern of autonomic dysregulation characterized by
increased cardiosympathetic and reduced cardioparasympathetic tone among TMD cases
compared to controls. Though the magnitude of most associations is modest, indices
reflecting autonomic function represent a set of biological processes that may contribute
unique variance to the prediction of TMD.
Smith, et al: Genetic Findings from the OPPERA Study
The final article in this Compendium examines genetic associations with TMD.13 In the
OPPERA heuristic model, commonly-occurring genetic variants are depicted as an
“upstream” set of etiologic influences because they regulate enzymes, neurotransmitters,
receptors and structural proteins that are essential for the biological processes occurring in
chronic pain. For the OPPERA Program, DNA samples extracted from whole blood were
genotyped for 3295 single nucleotide polymorphisms (SNPs) representing 358 genes
involved in biological systems relevant to pain perception. This study represents the first
genetic association study of TMD to investigate an extensive panel of pain related candidate
genes.
Data quality procedures and statistical analysis methods are described in detail. Given the
modest number of TMD cases available in the OPPERA cohort, this genetic association
study supplemented the OPPERA sample with 182 additional TMD cases from another
project at the University of North Carolina (the UNC cohort). A two-tier analytic approach
was adopted, in which a small subset of genes investigated in previous studies of pain was
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hypothesized a priori as high priority and subjected to a less stringent correction for
determining statistical significance. The remaining genes were considered Tier 2, or
exploratory genes, with an increased error correction threshold.
For Tier 1 genes, eight SNPs were noteworthy because the p-value for their association with
TMD diverged from the p-value distribution expected under the null hypothesis. They
comprised 3 SNPs tagging adrenergic receptor genes (1 SNP of ADRA2C, 2 ADRA1D
SNPs), a SNP of the catechol-O-methyltransferase gene (COMT), a delta opioid receptor
(OPRD1) gene SNP, two SNPs in the region of the interleukin 10 (IL10) gene, and a SNP of
the of the GRIN2A ionotropic N-methyl-D-aspartate (NMDA) receptor 2A gene. For most
of these SNPs, minor allele frequency was at least 20%, and odds ratios approximated either
1.5, signifying greater odds of TMD associated with the minor allele, or 0.6 signifying a
similar magnitude of a protective association. (Reverse coding for the major allele would
produce corresponding odds ratios of 1/1.5 = 0.7 and 1/0.6 = 1.7.) Some larger odds ratios
were observed for SNPs with lower allele frequency.
For Tier 2 genes, nine SNPs across six genes were associated with TMD case status with p-
values exceeding what would be expected due to chance. Three of the SNPs were in the
region of the glucocorticoid gene (NR3C1), one was a SNP of the serotonin 2A receptor
gene (HTR2A), two SNPs were on the calcium/calmodulin-dependent protein kinase 4 gene
(CAMK4), one was in the muscarinic cholinergic receptor 2 (CHRM2) gene, one SNP was
in the interferon-related developmental regulator 1 (IFRD1) gene, and one SNP was in the G
protein-coupled receptor kinase 5 (GRK5) gene. While the authors acknowledge the need
for replication of the results, and the findings strongly suggest that multiple genetic loci and
biological pathways contribute to risk for TMD.
Conclusions and Future Directions
Taken together, the findings across this set of manuscripts demonstrate that these TMD
cases differ from controls across multiple phenotypic domains. Specifically, odds of TMD
were associated with socio-demographic factors, clinical variables, psychological
functioning, pain sensitivity, and autonomic responses. Also, several novel genetic
associations with TMD were identified, providing clues to the biological pathways that may
contribute to TMD pathophysiology.
Not surprisingly, the strongest associations with TMD were observed for measures related to
the manifest features of TMD: bodily tenderness (e.g. pressure pain thresholds) and salience
of symptoms (e.g. somatic awareness). Odds ratios were smaller, signifying weaker
associations, for measures of phenotypes depicted as more distal mechanisms in the
OPPERA heuristic model, including mood, autonomic function, impaired temporal
regulation of pain and genetic variants. While this observation is subject to several of the
caveats considered below, the findings provide preliminary support for the OPPERA
heuristic model. Further, the broad range of phenotypic domains that distinguish cases from
controls reflects the complex and multidimensional nature of TMD etiopathogenesis, which
we have referred to as a “web of causation.”6,8
As noted above, the term “risk factors” connotes etiologic events and characteristics, yet for
many risk factors of interest, this case-control study evaluates association, not causation.
Indeed, for some of the phenotypic variables it is plausible that the measured characteristic
represents both a cause and a consequence of TMD. For example, Ohrbach et al8 discuss the
evidence showing that parafunctional behaviors such as clenching can not only contribute to
onset of TMD, but can also occur as an adaptive response to it. Similar, bi-directional
associations can easily be envisaged for many measures of psychological distress and pain
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amplification. The cross-sectional findings presented in this Compendium do not address
this issue and the phenotypic findings presented must be interpreted only as associations. In
principle, odds ratios for associations with these “bi-directional” phenotypes will be greater
than the causal odds ratio that would be observed if only the etiological component of the
association could be dissected. This principle probably accounts for several of the very
strong associations observed for several clinical measures, and it may contribute to strong
associations seen for measures such as somatic awareness. The prospective study of the
OPPERA Project is designed to determine the temporal sequence in which phenotypic risk
factors and onset of TMD unfold, and ultimately to identify true causal determinants of
TMD. Notable exceptions to these limitations are genotypes and other immutable
characteristics: age, gender, and race/ethnicity.
Another interpretive consideration for these results is that the association of risk factors with
TMD was examined in univariate fashion in these analyses, controlling only for study site,
age, gender and race. It is likely that the magnitude of these associations, and possibly even
their direction, will change in multivariate analyses that consider combined contributions of
more than one putative risk factor to TMD. For example, in the analysis of psychological
variables, both perceived stress and negative affect were associated with increased odds of
TMD; however, it is conceivable that after statistical adjustment for perceived stress,
negative affect may no longer show a significant association with TMD. Furthermore, most
of these analyses evaluate odds of TMD only as a linear function of the measured
phenotype, yet non-linear relationships are likely for some measures, and might be
informative about processes underlying the association. The OPPERA program will be
investigating such relationships in the near future as case accrual and data collection ends.
There are several additional future directions that the OPPERA investigators plan to pursue
to exploit this very rich compilation of phenotypic and genotypic data that promises to
illuminate the pathophysiological processes that contribute to TMD. For example, we have
not yet explored the benefits of incorporating measures across phenotypic domains (e.g.
psychological and pain sensitivity measures) into multivariable analyses to increase our
ability to disentangle combined etiologic influences and to distinguish cases from controls. It
seems plausible that individuals with high risk phenotypes in both psychological distress and
pain amplification domains would show greater odds of TMD than those people with a risk
phenotype in only one of these domains. Analyses to empirically examine this hypothesis
will be conducted in the future. Also, the OPPERA heuristic model proposes that the
association of genetic factors with TMD risk is mediated by the intermediate phenotypes of
pain amplification and psychological distress, which interact with environmental exposures
to influence TMD risk. Therefore, OPPERA investigators plan to conduct association
studies to directly identify genetic factors contributing to pain amplification and
psychological distress. Of course, these planned analyses represent precursors to the ultimate
goal of the OPPERA Program, which is to build and then test a multivariable model
designed to identify true causal determinants of new onset TMD, as well as its persistence.
The results of these first case-control studies support our conceptual model, which increases
our confidence that these future efforts will be successful.
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